Search

Displaying results 3491 - 3500 of 10000 in total
  1. Drug

    DDP-225

    go.drugbank.com/drugs/DB05642
    Investigational

    Dynogen licensed preclinical and clinical data related to DDP225 from Mitsubishi Pharma in October 2003. … The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases.

  2. Drug

    BBIBP-CorV

    go.drugbank.com/drugs/DB15807
    Investigational

    As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … Investigation shows this vaccine induces neutralizing antibodies in several mammalian species while also showing protective efficacy with SARS-CoV-2 challenge in rhesus macaques[A219763].

  3. Drug

    Phentolamine

    go.drugbank.com/drugs/DB00692
    ApprovedInvestigational

    While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral

    Synonyms: 2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazolineProducts: Rogitine 5mg/vial
  4. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause

  5. Drug

    Halofuginone

    go.drugbank.com/drugs/DB04866
    InvestigationalVet approved

    Food and Drug Administration in March, 2000. … Halofuginone also effectively suppresses tumor progression and metastasis in mice.

  6. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. … It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.

  7. Drug

    Dimazole

    go.drugbank.com/drugs/DB13858
    ApprovedWithdrawn

    Dimazole (diamthazole) is an antifungal. It was withdrawn in Franch in 1972 due to neuropsychiatric reactions.

  8. Drug

    Amoxapine

    go.drugbank.com/drugs/DB00543
    Approved

    The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation.

    Categories: Dopamine D2 Receptor Antagonists
  9. Drug

    Influenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14587
    ApprovedInvestigational

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Efluelda Tetra Injektionssuspension in einer Fertigspritze, SKYCellflu Trivalent Solution for Injection in Prefilled Syringe 0.25ml
  10. Drug

    Rosiglitazone

    go.drugbank.com/drugs/DB00412
    ApprovedInvestigational

    Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. … Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone.

    International brands: DH-RosidiaCategories: Drugs Used in Diabetes